All Oncology News

Michael E. Hurwitz, MD, PhD, highlights the role of second-generation androgen blockers in nonmetastatic castration-resistant prostate cancer, how these agents compare, and active areas of investigation.

December 28, 2020 - The investigational selective estrogen receptor degrader SAR439859 elicited clinical, on-target activity in patients with heavily pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer, even in the presence of multiple resistance mechanisms.

Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.

Stephen Liu, MD, discusses some pivotal data that support the expanding reach of targeted therapy in non–small cell lung cancer.

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

The American Association for Cancer Research revealed a comprehensive, first-of-its-kind AACR Cancer Disparities Progress Report, which highlights disparities in cancer incidence, diagnosis, treatment, and survival, along with a heavy emphasis on racial and ethnic disparities in cancer care.

Michael J. Robertson, MD, discusses the value of fellowship, choosing a career path, and the second epiphany that led him to focus on one of the hottest topics in oncology years before it became a viable treatment option.

December 23, 2020 - Pacritinib, when delivered at a twice-daily dose of 200 mg, was found to demonstrate clinical activity with an acceptable toxicity profile in patients with myelofibrosis and severe thrombocytopenia.

December 23, 2020 — Nivolumab in combination with temozolomide and radiation treatment failed to result in a statistically significant improvement in overall survival in patients with newly diagnosed glioblastoma multiforme with MGMT promoter methylation following surgical resection of the tumor.

December 23, 2020 - The European Commission has approved the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, to be administered via a subcutaneous injection in the treatment of patients with early and metastatic HER2-positive breast cancer.

December 23, 2020 - The FDA has granted an orphan drug designation to the mismatched, double-stranded RNA molecule rintatolimod for the treatment of patients with pancreatic cancer.

December 23, 2020 — Findings from the International, Prospective ALCL-Relapse trial showed that allogeneic SCT after reinduction chemotherapy can lead to survival improvements in children and adolescents with high-risk relapsed or refractory anaplastic large cell lymphoma, provide more insight into how to treat this population.

December 23, 2020 — Although SGX942 was found to induce clinically meaningful reductions in severe oral mucositis vs placebo in patients with head and neck cancer, the benefit failed to reach statistical significance, thus missing the primary end point of the phase 3 DOM-INNATE study.

December 23, 2020 - Entrectinib continued to demonstrate clinically meaningful, durable responses with a manageable toxicity profile in patients with NTRK fusion–positive sarcoma.

December 23, 2020 - The FDA has updated the prescribing information for ibrutinib to include safety and efficacy data for the agent in combination with rituximab in the treatment of patients with Waldenström macroglobulinemia.

December 22, 2020 - Patients with polycythemia vera who received ropeginterferon alfa-2b had a higher likelihood of being phlebotomy free in the fourth or fifth year of treatment vs those who received best available therapy.

December 22, 2020 — Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor–positive, estrogen receptor–positive metastatic breast cancer.

December 22, 2020 - Idasanutlin, an investigational MDM2 antagonist that leads to increased p53 activity, led to hematologic responses in about two-thirds of patients with hydroxyurea-resistant polycythemia vera, but was associated with frequent discontinuation.

December 22, 2020 — Intravesical Bacillus Calmette-Guerin in combination with N-803 was found to induce a complete response rate of 72% in patients with non-muscle invasive bladder cancer in high-risk carcinoma in situ disease, meeting the primary end point of the phase 2/3 QUILT 3.032 trial.

December 22, 2020 - Minimum residual disease negativity in the bone marrow and peripheral blood prior to autologous stem cell transplant predicts better progression-free survival and overall survival in younger patients with mantle cell lymphoma.

The small interfering RNA therapeutic STP705 has been found to induce high rates of histological clearance with a favorable toxicity profile in patients with squamous cell skin cancer.

December 22, 2020 — The FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme.

December 21, 2020 — The addition of gilteritinib to azacitidine failed to significantly improve overall survival vs azacitidine alone in patients with newly diagnosed FLT3-mutated acute myeloid leukemia who were not eligible for intensive induction chemotherapy, failing to meet the primary end point of the LACEWING trial.

December 21, 2020 - Cabozantinib was found to significantly improve progression-free survival compared with placebo in patients with dedifferentiated thyroid cancer who are refractory to radioiodine and have progressed following up to 2 prior VEGF-targeted treatments.

December 21, 2020 - The submission of a biologics license application to the FDA has been initiated for JZP-458 for use as a component of a multiagent chemotherapy regimen in the treatment of adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.

Matthew P. Goetz, MD, discusses ongoing research in the setting of ESR1-mutant, ER–positive, HER2-negative metastatic breast cancer.

December 21, 2020 — The 5-drug regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide showed a tolerable safety profile and encouraging antitumor activity with complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

December 21, 2020 - Interferon-alpha can delay and possibly prevent post-PV myelofibrosis and improve survival in patients with polycythemia vera.

December 21, 2020 - A rolling submission of the biologics license application for the BCMA-directed CAR T-cell product ciltacabtagene autoleucel for use in adults with relapsed/refractory multiple myeloma has been initiated to the FDA.